Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment

Acute Myeloid Leukemia Clinical Trial

Official title: A Pilot Study to Determine the Safety and Efficacy of Using Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment

Status Active, not recruiting

Clinical Trial Summary

By doing this study, researchers hope to learn the following:

• If providing hyperbaric oxygen (HBO) therapy prior to an umbilical cord blood (UBC) transplant will help to improve the homing process

• The safety of HBO administration in the setting of the UBC transplant

• The effects of HBO therapy on the engraftment process

Clinical Trial Description

Research has suggested that high levels of erythropoietin (EPO) decreases the ability of infused umbilical cord stem cells to home to the bone marrow. The investigators will investigate the use of hyperbaric oxygen (HBO) therapy to decrease the plasma concentrations of EPO prior to UBC transplant and evaluate the resulting impact on UBC homing. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Hodgkin Disease
• Hodgkins Lymphoma
• Leukemia
• Leukemia, Lymphoid
• Leukemia, Myeloid, Acute
• Lymphoma
• Lymphoma, Non-Hodgkin
• Myelodysplastic Syndrome (MDS)
• Myelodysplastic Syndromes
• Non-Hodgkins Lymphoma
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Preleukemia

• NCT number: NCT02099266
• Study type: Interventional
• Source: University of Kansas Medical Center
• Status: Active, not recruiting
• Phase: N/A
• Start date: June 2013
• Completion date: March 2016